February 2, 2026 4:41pm

Although indexes flared and C&GT sector flicked-up

Friday’s jobs report will be delayed because of the partial government shutdown with the expectation to show an increase of 55,000 jobs and the unemployment rate to hold steady at 4.4%.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: Digging-in or shoveling out, sector earnings and econs … https://www.regmedinvestors.com/articles/14292

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Monday: The Dow closed UP +515.19 points or +1.05%, the S&P closed UP +37.41 points or +0.54% while the Nasdaq closed UP +130.292 points or +0.56%

  • Theme of the session: looking past the C&GT sector’s recent losses

Monday’s (my) 40-company covered sector’s advance/decline line opened positive with 23 incliners, 16 decliners and 1 flat, ending with a positive close of 29 incliners, 10 decliners and 1 flat

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • U.S. factory activity in January expanded for the first time in a year, boosted by surges in new orders and production, the Institute for Supply Management manufacturing index showed a reading of 52.6 for the month, representing the % of surveyed companies reporting expansion. The level represented a 4.7-point increase from December and was well ahead of the consensus estimate for 48.4. Prior to the last expansion reading, the index was in contraction territory, or below 50, for 26 straight months. Within the survey, the new orders index jumped 9.7 points to 57.1, while production surged 5.2 points to 55.9. Both were the highest since February 2022.

The CBOE Fear (VIX) index, Monday closed at 16.53, after Friday’s 17.66, Thursday’s 16.89, Wednesday’s16.40, after Tuesday’s 16.22 and last Monday’s 16.09,

Metrics: Monday …

  • The RUT was up +26.54 points or +1.02%,
  • The XLV was up +0.90 points or +0.58%,
  • The NBI was up +64.71 points or +1.11%;
  • The XBI was up +2.60 points or +2.08%
  • The IWM was up +2.45 or +0.94%;
  • The IBB was up +1.71 points or +0.99%,
  • The VIX was down -0.91 points or -5.22% at to 16.53

 

Q1/26 February – 1 positive session

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Monday Closing UP (10 of 29) 

  • Arrowhead Pharmaceuticals (ARWR +$3.67 after Friday’s +$0.21),
  • Vertex (VRTX +$2.11 after Friday’s -$5.78),
  • uniQure NV (QURE +$1.98 after Friday’s -$0.94),
  • CRISPR Therapeutics (CRSP +$1.35 after Friday’s -$3.39)
  • Capricor Therapeutics (CAPR +$1.20),
  • Alnylam Pharmaceuticals (ALNY +$1.05 after Friday’s -$8.73),
  • IQIA Holdings (IQV +$1.01 after Friday’s -$5.33),
  • Vericel (VCEL +$0.96),
  • Dyne Therapeutics (DYN +$0.87 after Friday’s +$0.01)
  • Supernus Therapeutics (SUPN +$0.62),

Flat (1)

  • Rocket Therapeutics (RCKT) 

Monday’s Closing DOWN (10 of 10): 

  • BioNTech (BNTX -$4.87 after Friday’s -$3.02),
  • Moderna (MRNA -$1.52 after Friday’s -$2.79),
  • Regenxbio (RGNX -$0.38),
  • Harvard Apparatus RT (OTCQB: HRGN -$0.10 after Friday’s $0.00)
  • Intellia Therapeutics (NTLA -$0.09),
  • Mesoblast (MESO -$0.06),
  • Solid Biosciences (SLDB -$0.03),
  • MiMedx (MDXG -$0.02),
  • Brainstorm Cell Therapeutics (BCLI -$0.01 after Friday’s +$0.05),
  • Prime Medicine (PRME -$0.01),

 

The Bottom Line: More of the … WHY

New month, big up …

As indexes ended Monday on a positive note, shaking off the past AI trade uncertainties as earnings flooded in.

Investors are also wondering what comes next after President Trump chose Kevin Warsh as his nominee to lead the Fed.

  • On the macro front, stocks rose after two readings of manufacturing sector activity unexpectedly improved in January.
  • Purchasing Managers' Indexes from S&P Global and the Institute for Supply Management saw their sharpest increase in production since May 2022. <Yahoo Finance>

 

Indexes are up, who cares why; is what I feel/write some days – a new month needs a good/positive start!

 

Since, the Q4 and FY25 earnings cycle is about to appear beginning 2/5 and 2 more on 2/14

•              2/5 – Arrowhead Pharmaceuticals (ARWR)

•              2/5 – IQVA Holdings (IQV)

•              2/12 – Alnylam Pharmaceuticals (ALNY), Vertex (VRTX)

•              2/13 – Moderna (MRNA)

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 1st week

  • Monday closed positive with 29 incliners, 10 decliners and 1 flat

January – 5th week:

  • 1/30 – Friday closed negative with 6 incliners, 32 decliners and 2 flat
  • 1/29 - Thursday closed positive with 22 incliners, 17 decliners and 1 flat
  • 1/28 - Wednesday closed negative with 4 incliners, 35 decliners and 1 flat
  • 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
  • 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Monday: Arrowhead Pharmaceuticals (ARWR), Vertex (VRTX) and UniQure NV (QURE)
  • Friday: Arrowhead Pharmaceuticals (ARWR), AxoGen (AXGN) and Brainstorm Cell Therapeutics (BCLI)

The worst three (3) in the session: Losers

  • Monday: BioNTech (BNTX), Moderna (MRNA) and Regenxbio (RGNX)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.